Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction
AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2018-04-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.cn/en_publish/2018/4/20180409.pdf |
id |
doaj-9ac8b8eb245d4bc8b3cf84493f11f0d9 |
---|---|
record_format |
Article |
spelling |
doaj-9ac8b8eb245d4bc8b3cf84493f11f0d92020-11-24T22:39:21ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982018-04-0111459360010.18240/ijo.2018.04.09Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunctionHo-Yun Kim0Ji-Eun Lee1Ha-Na Oh2Ju-Whan Song3Sang-Youp Han4Jong-Soo Lee5Department of Ophthalmology, Maryknoll Medical Center, Busan 48972, South KoreaDepartment of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan 50612, South KoreaDepartment of Ophthalmology, Inje University Baek Hospital, Busan 47392, South KoreaDepartment of Ophthalmology, Kosin University hospital, Busan 49267, South KoreaSungmo Eye Clinic, Busan 48064, South KoreaDepartment of Ophthalmology, Pusan National University Hospital, Busan 49241, South Korea; Medical Research Institute, Pusan National University Hospital, Busan 49241, South KoreaAIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI). RESULTS: In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI; P<0.001), tBUT (P=0.004), Schirmer test score (P=0.008) and LMT (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in OSDI (P<0.001), tBUT (P=0.001), Schirmer test score (P=0.029), CS score (P=0.047), LMT (P=0.002), CI (P=0.030) were improved better in the experimental group than in the control group at 3mo. However, there was no significant difference between the two groups in MGS (P=0.67). CONCLUSION: In dry eyes with MGD, 0.05% CsA improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation.http://www.ijo.cn/en_publish/2018/4/20180409.pdf6000.05% cyclosporine0.1% hyauronatemeibomian gland dysfunctiondry eye |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ho-Yun Kim Ji-Eun Lee Ha-Na Oh Ju-Whan Song Sang-Youp Han Jong-Soo Lee |
spellingShingle |
Ho-Yun Kim Ji-Eun Lee Ha-Na Oh Ju-Whan Song Sang-Youp Han Jong-Soo Lee Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction International Journal of Ophthalmology 600 0.05% cyclosporine 0.1% hyauronate meibomian gland dysfunction dry eye |
author_facet |
Ho-Yun Kim Ji-Eun Lee Ha-Na Oh Ju-Whan Song Sang-Youp Han Jong-Soo Lee |
author_sort |
Ho-Yun Kim |
title |
Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction |
title_short |
Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction |
title_full |
Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction |
title_fullStr |
Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction |
title_full_unstemmed |
Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction |
title_sort |
clinical efficacy of combined topical 0.05% cyclosporine a and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction |
publisher |
Press of International Journal of Ophthalmology (IJO PRESS) |
series |
International Journal of Ophthalmology |
issn |
2222-3959 2227-4898 |
publishDate |
2018-04-01 |
description |
AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis®, Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD).
METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0.05% CsA and preservative free sodium hyaluronate vehicle (experimental group, n=74 eyes) and subjects treated with the preservative free sodium hyaluronate vehicle (control group, n=32 eyes). They were evaluated at baseline and 1, 2, and 3mo for subjective symptoms and objective signs including tear film break-up time (tBUT), Schirmer test, corneal staining (CS) score, lid margin telangiectasia (LMT), meibomian gland secretion (MGS), and conjunctival injection (CI).
RESULTS: In the short-term treatment, the experimental group showed a statistically significant improvement in the ocular surface disease index (OSDI; P<0.001), tBUT (P=0.004), Schirmer test score (P=0.008) and LMT (P=0.021) by repeated measure ANOVA. Additionally, mean changes from baseline in OSDI (P<0.001), tBUT (P=0.001), Schirmer test score (P=0.029), CS score (P=0.047), LMT (P=0.002), CI (P=0.030) were improved better in the experimental group than in the control group at 3mo. However, there was no significant difference between the two groups in MGS (P=0.67).
CONCLUSION: In dry eyes with MGD, 0.05% CsA improves the tear film stability as well as subjective ocular discomfort, and is effective in controlling lid margin inflammation. |
topic |
600 0.05% cyclosporine 0.1% hyauronate meibomian gland dysfunction dry eye |
url |
http://www.ijo.cn/en_publish/2018/4/20180409.pdf |
work_keys_str_mv |
AT hoyunkim clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction AT jieunlee clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction AT hanaoh clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction AT juwhansong clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction AT sangyouphan clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction AT jongsoolee clinicalefficacyofcombinedtopical005cyclosporineaand01sodiumhyaluronateinthedryeyeswithmeibomianglanddysfunction |
_version_ |
1725709392682156032 |